216 related articles for article (PubMed ID: 20237102)
1. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections.
Juréen P; Angeby K; Sturegård E; Chryssanthou E; Giske CG; Werngren J; Nordvall M; Johansson A; Kahlmeter G; Hoffner S; Schön T
J Clin Microbiol; 2010 May; 48(5):1853-8. PubMed ID: 20237102
[TBL] [Abstract][Full Text] [Related]
2. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.
Angeby KA; Jureen P; Giske CG; Chryssanthou E; Sturegård E; Nordvall M; Johansson AG; Werngren J; Kahlmeter G; Hoffner SE; Schön T
J Antimicrob Chemother; 2010 May; 65(5):946-52. PubMed ID: 20332195
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.
Schön T; Juréen P; Giske CG; Chryssanthou E; Sturegård E; Werngren J; Kahlmeter G; Hoffner SE; Angeby KA
J Antimicrob Chemother; 2009 Oct; 64(4):786-93. PubMed ID: 19633001
[TBL] [Abstract][Full Text] [Related]
4. Little difference between minimum inhibitory concentrations of Mycobacterium tuberculosis wild-type organisms determined with BACTEC MGIT 960 and Middlebrook 7H10.
Sturegård E; Ängeby KA; Werngren J; Juréen P; Kronvall G; Giske CG; Kahlmeter G; Schön T
Clin Microbiol Infect; 2015 Feb; 21(2):148.e5-7. PubMed ID: 25640156
[TBL] [Abstract][Full Text] [Related]
5.
Dijkstra JA; van der Laan T; Akkerman OW; Bolhuis MS; de Lange WCM; Kosterink JGW; van der Werf TS; Alffenaar JWC; van Soolingen D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311078
[TBL] [Abstract][Full Text] [Related]
6. Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.
Werngren J; Sturegård E; Juréen P; Ängeby K; Hoffner S; Schön T
Antimicrob Agents Chemother; 2012 Mar; 56(3):1253-7. PubMed ID: 22203587
[TBL] [Abstract][Full Text] [Related]
7. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System.
Rodrigues C; Jani J; Shenai S; Thakkar P; Siddiqi S; Mehta A
Int J Tuberc Lung Dis; 2008 Dec; 12(12):1449-55. PubMed ID: 19017456
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis.
Sirgel FA; Tait M; Warren RM; Streicher EM; Böttger EC; van Helden PD; Gey van Pittius NC; Coetzee G; Hoosain EY; Chabula-Nxiweni M; Hayes C; Victor TC; Trollip A
Microb Drug Resist; 2012 Apr; 18(2):193-7. PubMed ID: 21732736
[TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.
Maus CE; Plikaytis BB; Shinnick TM
Antimicrob Agents Chemother; 2005 Aug; 49(8):3192-7. PubMed ID: 16048924
[TBL] [Abstract][Full Text] [Related]
10. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis.
Schön T; Juréen P; Chryssanthou E; Giske CG; Sturegård E; Kahlmeter G; Hoffner S; Angeby KA
Int J Tuberc Lung Dis; 2011 Apr; 15(4):502-9. PubMed ID: 21396210
[TBL] [Abstract][Full Text] [Related]
11. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.
Keller PM; Hömke R; Ritter C; Valsesia G; Bloemberg GV; Böttger EC
Antimicrob Agents Chemother; 2015 Jul; 59(7):4352-5. PubMed ID: 25941226
[TBL] [Abstract][Full Text] [Related]
12. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis.
Engström A; Perskvist N; Werngren J; Hoffner SE; Juréen P
J Antimicrob Chemother; 2011 Jun; 66(6):1247-54. PubMed ID: 21427106
[TBL] [Abstract][Full Text] [Related]
13. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials.
Rüsch-Gerdes S; Pfyffer GE; Casal M; Chadwick M; Siddiqi S
J Clin Microbiol; 2006 Mar; 44(3):688-92. PubMed ID: 16517840
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis.
Via LE; Cho SN; Hwang S; Bang H; Park SK; Kang HS; Jeon D; Min SY; Oh T; Kim Y; Kim YM; Rajan V; Wong SY; Shamputa IC; Carroll M; Goldfeder L; Lee SA; Holland SM; Eum S; Lee H; Barry CE
J Clin Microbiol; 2010 Feb; 48(2):402-11. PubMed ID: 20032248
[TBL] [Abstract][Full Text] [Related]
15. Mycobacterium tuberculosis rrs A1401G mutation correlates with high-level resistance to kanamycin, amikacin, and capreomycin in clinical isolates from mainland China.
Du Q; Dai G; Long Q; Yu X; Dong L; Huang H; Xie J
Diagn Microbiol Infect Dis; 2013 Oct; 77(2):138-42. PubMed ID: 23948547
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of the in vitro antimycobacterial activities of six aminoglycoside antibiotics using an agar dilution method.
Udou T
J Chemother; 2006 Dec; 18(6):610-6. PubMed ID: 17267338
[TBL] [Abstract][Full Text] [Related]
17. Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system.
Torrea G; Coeck N; Desmaretz C; Van De Parre T; Van Poucke T; Lounis N; de Jong BC; Rigouts L
J Antimicrob Chemother; 2015 Aug; 70(8):2300-5. PubMed ID: 25977401
[TBL] [Abstract][Full Text] [Related]
18. Co-occurrence of amikacin-resistant and -susceptible Mycobacterium tuberculosis isolates in clinical samples from Beijing, China.
Zhang X; Zhao B; Huang H; Zhu Y; Peng J; Dai G; Jiang G; Liu L; Zhao Y; Jin Q
J Antimicrob Chemother; 2013 Jul; 68(7):1537-42. PubMed ID: 23539239
[TBL] [Abstract][Full Text] [Related]
19. Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France.
Brossier F; Pham A; Bernard C; Aubry A; Jarlier V; Veziris N; Sougakoff W;
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895017
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of the BACTEC MGIT 960 system for drug susceptibility testing of Mycobacterium tuberculosis isolates compared with the proportion method on solid media].
Abe C; Aono A; Hirano K
Kekkaku; 2001 Oct; 76(10):657-62. PubMed ID: 11712386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
